• Home
  • Subscribe
  • About Our Show
  • Guests
      About The ShowDr BellosDr FeskoDr GudinDr HilborneDr MasonDr RackeDr WaheedDr WohlgemuthMike LukasTammy Gerimini
  • Quest Diagnostics

Diagnostics Dialogues

Dr Gudin

Episodes

Trends in drug testing resulting from the COVID-19 pandemic

Wednesday Aug 25, 2021

Trends in drug testing resulting from the COVID-19 pandemic

Wednesday Aug 25, 2021

The convergence of the opioid epidemic and the coronavirus disease 2019 (COVID-19) pandemic has created new healthcare challenges. Health systems, from a system- and individual clinician-level, are more important than ever in the pursuit of addressing the epidemic within the pandemic. In this session, Dr Gudin discusses: Recently-published data by Quest that demonstrates decreased drug testing overall, with increased positivity for high-risk drugs and dangerous drug combinations  Tools and practices for clinicians to assess and stratify patients for potential prescription drug abuse System-level strategies that employ an integrated care delivery approach, including leveraging community and diagnostics partnerships, to support impacted patient populations Jeffrey Gudin, MD; Executive Director, Medical Affairs, Drug Monitoring & Toxicology Dr Gudin is an active speaker and advisor whose clinical and research interests include postoperative pain management; opioid abuse, and potential solutions; and increasing clinical awareness of pain assessment and risk management. Board-certified in pain management, addiction medicine, and hospice and palliative medicine, Dr Gudin is also a medical acupuncturist. He serves as co-Editor-at-Large for Practical Pain Management.

Read more

Quest, Quest Diagnostics, the associated logo, Nichols Institute, and all associated Quest Diagnostics marks are the registered trademarks of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2000-2022 Quest Diagnostics Incorporated. All rights reserved.

Podcast Powered By Podbean